Navigating Zepbound Doses: Understanding Current Shortages and Your Options

Last reviewed: June 27, 2026

Last updated: June 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (tirzepatide) shortages have created gaps in treatment access for patients managing weight loss and metabolic health. PlexusDx addresses this challenge by delivering compounded tirzepatide injection from licensed 503A pharmacies, ensuring continuity of care without membership fees or insurance barriers across all 50 states.

Why Zepbound Supply Interruptions Affect Patient Care

Brand-name Zepbound availability fluctuates due to manufacturing capacity, import regulations, and surging demand following its FDA approval for chronic weight management. When patients lose access mid-treatment, stopping GLP-1 therapy abruptly can reverse metabolic benefits and complicate long-term weight goals. Compounded alternatives bridge these gaps, allowing uninterrupted dosing schedules without waiting lists or authorization delays.

The FDA recognizes compounded tirzepatide from licensed 503A pharmacies as a legitimate pathway for patient access during brand-name shortages. These formulations undergo the same quality standards as brand medications, including sterility testing, potency verification, and contamination screening. PlexusDx sources all injectable tirzepatide from 503A facilities, not 503B bulk manufacturers, ensuring pharmaceutical-grade integrity.

Compounded Tirzepatide Injection: Clinical Equivalence and Mechanism

Tirzepatide functions as a dual GLP-1 and GIP receptor agonist, activating two separate hunger and metabolism pathways simultaneously. This dual mechanism produces greater weight reduction than GLP-1-only medications like semaglutide in clinical trials, with patients typically losing 20–25% of body weight over 72 weeks. PlexusDx compounded tirzepatide delivers identical active pharmaceutical ingredients at the same potency as the brand formulation.

The medication works by slowing gastric emptying, increasing satiety signals to the brain, and improving insulin sensitivity in muscle and liver cells. Starting doses begin low (2.5 mg weekly) to allow tolerability assessment, then advance based on individual response and side-effect profile. Because PlexusDx pricing remains flat across dose escalations, patients can increase their therapeutic dose without cost penalties.

PlexusDx Tirzepatide Options and Pricing Transparency

PlexusDx offers compounded tirzepatide injection at $289/mo month-to-month, or from $249/mo on the 6-month plan across three commitment tiers, with no price increase as doses advance. This flat-rate structure removes cost barriers to optimization—your dose may need to go up, but your price won't. Patients also benefit from HSA and FSA eligibility, reducing out-of-pocket expenses through pre-tax savings accounts.

For those exploring dual-compound therapy, PlexusDx's GLP-Squared Injection combines semaglutide and tirzepatide in a single formulation, at $289/mo month-to-month, or from $249/mo on the 6-month plan. This option suits patients seeking sequential exposure to both mechanisms or those requiring staggered dosing protocols. All medications ship discreetly nationwide with no membership fees, insurance requirements, or prior authorization delays.

Precision Peptide Genetic Testing and Personalized Response Prediction

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Genetic data helps clinicians anticipate dose tolerance, nausea risk, and long-term adherence likelihood before escalating therapy. Patients with specific GLP1R variants may respond robustly at lower doses, while those with FTO risk alleles often benefit from higher maintenance dosing. This precision approach accelerates the path to therapeutic dose and reduces trial-and-error adjustments, allowing faster achievement of weight and metabolic goals.

Navigating Side Effects and Treatment Tolerability

Early tirzepatide side effects—nausea, vomiting, constipation, and appetite suppression—peak during dose escalation and typically resolve within 1–2 weeks. Strategies to minimize discomfort include eating smaller, protein-rich meals, staying hydrated, and spacing dose increases by 4 weeks rather than rushing to maintenance. PlexusDx clinical protocols provide detailed tolerability guidance, and providers can adjust dosing cadence based on individual symptom reports.

Severe or persistent side effects warrant dose reduction or medication switch; compounded alternatives like semaglutide injection ($189/mo) or microdose GLP-1 protocol ($129/mo) offer lower-intensity options if tirzepatide proves intolerant. Long-term safety data from 2+ year studies shows tirzepatide maintains efficacy without significant cumulative toxicity, though pancreatitis and thyroid monitoring remain standard precautions for all GLP-1 therapy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Will compounded tirzepatide work the same as brand-name Zepbound?

Yes. PlexusDx compounded tirzepatide contains identical active pharmaceutical ingredients at the same concentration as Zepbound, sourced from licensed 503A pharmacies. The efficacy, mechanism, and side-effect profile are equivalent; only the manufacturing source and pricing differ, with PlexusDx at $289/mo month-to-month, or from $249/mo on the 6-month plan.

How much weight can I expect to lose with tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is compounded tirzepatide available in all states without insurance?

PlexusDx delivers compounded tirzepatide injection to all 50 states without insurance requirements, membership fees, or prior authorization. HSA and FSA accounts are accepted, and patients pay the flat rate of $249/month regardless of dose level.

What are the main side effects of tirzepatide?

Early side effects include nausea, vomiting, constipation, and decreased appetite, typically resolving within 1–2 weeks of each dose increase. Serious but rare adverse events include pancreatitis and gallbladder issues; thyroid function should be monitored. PlexusDx providers assess tolerability at each visit and adjust protocols accordingly.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to Zepbound or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Zepbound Doses
• Fridays Zepbound
• Hims Zepbound
• Form Health Zepbound

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.